New pharmacological strategies for the treatment of pulmonary fibrosis

Therapeutic Advances in Respiratory Disease

Volumn 4, Issue 6, 2010, Pages 353-366

  Gogali, Athena ^a   Wells, Athol U ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

idiopathic pulmonary fibrosis; pulmonary fibrosis; treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ANGIOTENSIN CONVERTING ENZYME 2; ANTILIPEMIC AGENT; AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PASIREOTIDE; PIRFENIDONE; PLACEBO; PREDNISOLONE; RECOMBINANT ANGIOTENSIN CONVERTING ENZYME 2; RECOMBINANT GAMMA INTERFERON; UNCLASSIFIED DRUG;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; FIBROSING ALVEOLITIS; HUMAN; IN VITRO STUDY; INFLAMMATION; LONG TERM CARE; LOW DRUG DOSE; LUNG DISEASE; LUNG FIBROSIS; MEDICAL SOCIETY; NEOPLASM; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RHEUMATOID ARTHRITIS; SARCOIDOSIS; WOUND; WOUND HEALING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INFLAMMATION; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PULMONARY FIBROSIS;

EID: 78649918614     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465810379454     Document Type: Review

References (64)

1. American Thoracic Society (ATS) and the European Respiratory Society (ERS) (2000) Idiopathic pulmonary fibrosis: Diagnosis and treatment: International consensus statement. Am J Respir Crit Care Med 161: 646-664.
2. Antoniou, K.M., Nicholson, A.G., Dimadi, M., Malagari, K., Latsi, P. and Rapti, A. ( 2006) Long term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur Respir J 28: 496-504.
3. Antoniou, K.M. and Wells, A.U. ( 2008) Scleroderma lung disease: evolving understanding in light of newer studies. Curr Opin Rheumatol 20: 686-691.
4. Atkins, S.R., Turesson, C., Myers, J.L., Tazelaar, H.D., Ryu, J.H., Matteson, E.L. et al. (2006) Morphologic and quantitative assessment of CD20+B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum 54: 635-641.
5. Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K. et al. (2005) Double blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171: 1040-1047.
6. Azuma, M., Nishioka, Y., Aono, Y., Inayama, M., Makino, H., Kishi, J. et al. (2007) Role of a1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Am J Respir Crit Care Med 176: 1243-1250.
7. Baughman, R.P., Drent, M., Kavuru, M., Judson, M.A., Costabel, U., du Bois, R.M. et al. (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174: 795-802.
8. Behr, J., Demedts, M., Buhl, R., Costabel, U., Dekhuijzen, R.P., Jansen, H.M. et al. (2009) Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial. Respir Res 10: 101.
9. Behr, J., Maier, K., Degenkolb, B., Krombach, F. and Vogelmeier, C. ( 1997) Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 156: 1897-1901.
10. Borie, R., Fabre, A., Prost, F., Marchal-Somme, J., Lebtahi, R., Marchand-Adam, S. et al. (2008) Activation of somatostatin receptors attenuates pulmonary fibrosis. Thorax 63: 251-258.
11. Bradley, B., Branley, H.M., Egan, J.J., Greaves, M.S., Hansell, D.M., Harrison, N.K. et al. (2008) Interstitial lung disease guideline: The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 63: 1-58.
12. Bullard, J.E., Wert, S.E., Whitsett, J.A., Dean, M. and Nogee, L.M. ( 2005) ABCA3 mutations associated with pediatric interstitial lung disease. Am J Respir Crit Care Med 172: 1026-1031.
13. Burdick, M.D., Murray, L.A., Keane, M.P., Xue, Y.Y. and Zisman, D.A. ( 2005) CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med 171: 261-268.
14. Cantin, A.M., Hubbard, R.C. and Crystal, R.G. ( 1989) Glutathione defficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 139: 370-372.
15. Chambers, R.C. ( 2008) Procoagulant signalling mechanisms in lung inflammation and fibrosis: Novel opportunities for pharmacological intervention? Br J Pharmacol 153(Suppl 1): S367-S378.
16. Corte, T.J., Wort, S.J. and Wells, A.U. (2009) Pulmonary hypertension in idiopathic pulmonary fibrosis: A review. Sarcoidosis Vasc Diffuse Lung Dis 26: 7-19.
17. Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijen, R., Jansen, H.M. et al. (2005) High dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353: 2229-2242.
18. Fiorucci, E., Lucantoni, G., Zotti, M., Li, B.E., Serpilli, M., Regimenti, P. et al. (2008) Colchicine, cyclophosphamide and prednisolone in the treatment of mild-moderate idiopathic pulmonary fibrosis: Comparison of three currently available therapeutic regimens. Eur Rev Med Pharmacol Sci 12: 105-111.
19. Gharaee-Kermani, M., Hu, B., Phan, S.H. and Gyetko, M.R. ( 2008) The role of urokinase in idiopathic pulmonary fibrosis and implication for therapy. Expert Opin Investig Drugs 17: 905-916.
20. Goh, N., Desai, S.R., Veeraraghavan, S., Hansell, D.M., Copley, S.J., Maher, T.M. et al. (2008) Interstitial lung disease in systemic sclerosis: A simple staging system. Am J Respir Crit Care Med 177: 1248-1254.
21. Hoyles, R.K., Ellis, R.W., Wellsbury, J., Lee, B., Newlands, P., Goh, N.S. et al. (2006) A multicenter, prospective, randomized double blind, placebo controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54: 3962-3970.
22. Hunninghake, G.W. ( 2005) Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med 353: 2285-2287.
23. Imokawa, S., Sato, A., Hayakawa, H., Kotani, M., Urano, T. and Takada, A. ( 1997) Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 156: 631-636.
24. Judson, M.A., Baughman, R.P., Costabel, U., Flavin, S. and Lo, K.H. ( 2008) Efficacy of infliximab in extrapulmonary sarcoidosis: Results from a randomised trial. Eur Respir J 31: 1189-1196.
25. Kass, D., Bridges, R.S., Borczuk, A. and Greenberg, S. ( 2007) Methionine aminopeptidase-2 as a selective target of myofibroblasts in pulmonary fibrosis. Am J Respir Cell Mol Biol 37: 193-201.
26. Khanna, D., Furst, D.E., Clements, P.J., Tashkin, D.P. and Eckman, M.H. ( 2008) Oral cyclophosphamide for active scleroderma lung disease: A decision analysis. Med Decis Making 28: 926-937.
27. Kinder, B.W., Collard, H.R. and King Jr., T.E. ( 2006) Anticoagulant therapy and idiopathic pulmonary fibrosis. Chest 130: 302-303.
28. King Jr, T.E., Albera, C., Bradford, W.Z., Costabel, U., Hormel, P., Lancaster, L. et al. (2009) Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): A multicentre, randomized, placebo-controlled trial. Lancet 374: 222-228.
29. King, T.E., Behr, J., Brown, K.K., du Bois, R.M., Lancaster, L., de Andrade, J.A. et al. (2008) BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177: 75-81.
30. Kobayashi, H., Gabazza, E.C., Taguchi, O., Wada, H., Takeya, H., Nishioka, J. et al. (1998) Protein C anticoagulant system in patients with interstitial lung disease. Am J Respir Crit Care Med 157: 1850-1854.
31. Koth, L.L. and Shepard, D. ( 2004) Integrins and pulmonary fibrosis, In: Lynch III, J.P. (ed.). Idiopathic Pulmonary Fibrosis, Marcel Dekker: New York, pp. 375-378.
32. Kubo, H., Nakayama, K., Yanai, M., Suzuki, T., Yamaya, M., Watanabe, M. et al. (2005) Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128: 1475-1482.
33. Lakatos, H.F., Thatcher, T.H., Kottmann, R.M., Garcia, T.M., Phipps, R.P. and Sime, P.J. ( 2007) The role of PPARs in lung fibrosis. PPAR Res 2007: 71323.
34. Li, X., Molina-Molina, M., Abdul-Hafez, A., Uhal, V., Xaubet, A. and Uhal, B.D. ( 2008) Angiotensin converting enzyme-2 is protective but down-regulated in human and experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol 295: 178-185.
35. Moller, D.R. ( 2003) Treatment of sarcoidosis from a basic science point of view. J Intern Med 253: 31-40.
36. Murray, L.A., Argentieri, R.L., Farrell, F.X., Bracht, M., Sheng, H., Whitaker, B. et al. (2008) Hyper-responsiveness of IPF/UIP fibroblasts: Interplay between TGFbeta1, IL-13 and CCL2. Int J Biochem Cell Biol 40: 2174-2182.
37. Myllårniemi, M., Lindholm, P., Ryynånen, M.J., Kliment, C.R., Salmenkivi, K., Keski-Oja, J. et al. (2008) Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis. Am J Respir Crit Care Med 177: 321-329.
38. Nakayama, S., Mukae, H., Samamoto, N., Kakugawa, T., Yoshika, S., Soda, H. et al. (2008) Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci 82: 210-217.
39. Nicholson, A.G., Colby, T.V., du Bois, R.M., Hansell, D.M. and Wells, A.U. ( 2000) The prognostic significance of the histological pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 162: 2213-2217.
40. Nishiyama, O., Kondoh, T., Kato, K., Kataoka, K., Ogawa, T., Watanabe, F. et al. (2008) Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 13: 394-399.
41. Noble, P.W. and Homer, R.J. ( 2004) Idiopathic pulmonary fibrosis: New insights into pathogenesis. Clin Chest Med 25: 749-758.
42. Piguet, P.F. and Vesin, C. ( 1994) Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 7: 515-518.
43. Raghu, G. ( 2009) Improving the standard of care for patients with idiopathic pulmonary fibrosis requires participation in clinical trials. Chest 136: 330-333.
44. Raghu, G., Brown, K., Costabel, U., Cottin, V., du Bois, R.M., Joseph, A. et al. (2008) Treatment of idiopathic pulmonary fibrosis with etanercept: An exploratory, placebo-controlled trial. Am J Respir Crit Care Med 178: 948-955.
45. Raghu, G. and Chang, J. ( 2004) Idiopathic pulmonary fibrosis: Current trends in management. Clin Chest Med 25: 621-636.
46. Raghu, G., Freudenburger, T.D. and Yang, S. ( 2006) High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 27: 136-142.
47. Roos, N., Poolalhon, N., Farge, D., Madelaine, I., Mauviel, A. and Verrechia, F. ( 2007) In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther 321: 583-589.
48. Saketkoo, L.A. and Espinoza, L.R. ( 2008) Reumatoid arthritis interstitial lung disease: Mycophenolate mofetil as an antifibrotic and disease modifying anti-rheumatic drug. Arch Intern Med 168: 1178.
49. Selman, M., Pardo, A., Barrera, L., Estrada, A., Watson, S.R., Wilson, K. et al. (2006) Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 173: 188-198.
50. Selman, M., Thannickal, V.J., Pardo, A., Zisman, D.A., Martinez, F.J. and Lynch 3rd., J.I. ( 2004) Idiopathic pulmonary fibrosis: Pathogenesis and therapeutic approaches. Drugs 64: 405-430.
51. Stagaki, E., Mountford, W.K., Lackland, D.T. and Judson, M.A. (2009) The treatment of lupus pernio: Results of 116 treatment courses in 54 patients. Chest 135: 468-476.
52. Strieter, R.M. ( 2005) Pathogenesis and natural history of usual interstitial pneumonia: The whole story or the last chapter of a long novel. Chest 128: 5268-5328.
53. Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M. et al. (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35: 821-829.
54. Tashkin, D.P., Elashoff, R., Clements, P.J., Roth, M.D., Furst, D.E., Silver, R.M. et al. (2007) Effects of 1 year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176: 1026-1034.
55. Thannickal, V.J., Toews, G.B., White, E.S., Lynch 3rd, J.P. and Martinez, F.J. ( 2004) Mechanisms of pulmonary fibrosis. Annu Rev Med 55: 395-417.
56. Uthman, I., Touma, Z. and Khoury, M. ( 2007) Cardiac sarcoidosis responding to monotherapy with infiximab. Clin Rheumatol 26: 2001-2003.
57. Vassallo, R. and Thomas, C.F. ( 2004) Advances in treatment of rheumatic interstitial lung disease. Curr Opin Rheumatol 16: 186-191.
58. Walters, D.M., Cho, H.Y. and Kleeberger, S.R. ( 2008) Oxidative stress and antioxidants in the pathogenesis of pulmonary fibrosis: A potential role for Nrf2. Antioxid Redox Signal 10: 321-332.
59. Wells, A.U. ( 2006) Antioxidant therapy in idiopathic pulmonary fibrosis: Hope is kindled. Eur Respir J 27: 664-666.
60. Wells, A.U. ( 2008) Infiximab in extrapulmonary sarcoidosis: Tantalising but inconclusive. Eur Respir J 31: 1148-1149.
61. Wells, A.U., Latsi, P. and McCune, W.J. ( 2007) Daily cyclophosphamide for scleroderma: Are patients with the most to gain underrepresented in this trial? Am J Respir Crit Care Med 176: 952-953.
62. Yasui, H., Gabazza, E.C., Taguchi, O., Risteli, J., Risteli, L., Wada, H. et al. (2000) Decreased protein C activation is associated with abnormal collagen turnover in the intraalveolar space of patients with interstitial lung disease. Clin Appl Thromb Hemost 6: 202-205.
63. Yu, H., Konigshoff, M., Jayachandran, A., Handley, D., Seeger, W., Kaminski, N. et al. (2008) Transgelin is a direct target of TGF-beta/Smad3-dependent epithelial cell migration in lung fibrosis. FASEB J 22: 1778-1789.
64. Zamora, A.C., Wolters, P.J., Collard, H.R., Connolly, M.K., Elicker, B.M., Webb, W.R. et al. (2008) Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 102: 150-155.